ArriVent BioPharma Inc AVBP
$29.12 $0.06 (0.21%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
AVBP Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, ArriVent BioPharma Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
ArriVent BioPharma Inc. Stock Analysis AVBP
United States Health Care Small Cap Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 77 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
ArriVent BioPharma Inc (AVBP) Chart
Financial Metrics & Statements of ArriVent BioPharma Inc (AVBP)
FAQ's for ArriVent BioPharma Inc (AVBP)
- As of August 2026, ArriVent BioPharma Inc AVBP is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ArriVent BioPharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in ArriVent BioPharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of ArriVent BioPharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of ArriVent BioPharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of ArriVent BioPharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for ArriVent BioPharma Inc (AVBP)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
